Robustness of clonogenic assays as a biomarker for cancer cell radiosensitivity

Toshiaki Matsui, Endang Nuryadi, Shuichiro Komatsu, Yuka Hirota, Atsushi Shibata, Takahiro Oike, Takashi Nakano

研究成果: Comment/debate査読

25 被引用数 (Scopus)


Photon radiation therapy is a major curative treatment for cancer. However, the lack of robust predictive biomarkers for radiosensitivity precludes personalized radiation therapy. Clonogenic assays are the gold standard method for measuring the radiosensitivity of cancer cells. Although a large number of publications describe the use of clonogenic assays to measure cancer cell radiosensitivity, the robustness of results from different studies is unclear. To address this, we conducted a comprehensive detailed literature search of 256 common cancer cell lines and identified the eight cell lines most-frequently examined for photon sensitivity using clonogenic assays. Survival endpoints and experimental parameters from all 620 relevant experiments were compiled and analyzed. We found that the coefficients of variation for SF2 (surviving fraction after 2 Gy irradiation) and for D10 (dose that yields a surviving fraction of 10%) were below 30% for all cell lines, indicating that SF2 and D10 have acceptable inter-assay precision. These data support further analysis of published data on clonogenic assays using SF2 and D10 as survival endpoints, which facilitates robust identification of biological profiles representative of cancer cell sensitivity to photons.

ジャーナルInternational journal of molecular sciences
出版ステータスPublished - 2019 9月 1

ASJC Scopus subject areas

  • 触媒
  • 分子生物学
  • 分光学
  • コンピュータ サイエンスの応用
  • 物理化学および理論化学
  • 有機化学
  • 無機化学


「Robustness of clonogenic assays as a biomarker for cancer cell radiosensitivity」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。